Farydak comes to mind......the key question here is whether the FDA wants more data (good news) or if they require an additional clinical trial (bad news).
if the FDA wants another clinical trial or if they need more data......if they need more data, than this still could get approved.....if the don't trust the outcome and want another clinical trial....then that is a problem.
No way would he have left a multi-million dollar position at Perrigo if it were not the case.
in support of approval for this product.
whether it be afterhours today or later this week......it will be a painful gap up for them to deal with.
I would say 20%.....just because 80% of managed money cannot own stocks of company's whose 10-K is not current....once it is released, billions of dollars will pour in.
is that the FDA adcom panel votes tend to sway towards the opinion of the the adcom member with the loudest opinion in the room...... sheep like behavior.
hadn't seen the VRX 10-K and wasn't sure that Valeant would be around for years to come? Answer: ABSOLUTELY NOT.
and higher she will go!!!